Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jul 27;9:e46767. doi: 10.2196/46767

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

©Wenjing Wang, Shengnan Zhao, Yaxin Wu, Wenshan Duan, Sibo Li, Zhen Li, Caiping Guo, Wen Wang, Tong Zhang, Hao Wu, Xiaojie Huang. Originally published in JMIR Public Health and Surveillance (https://publichealth.jmir.org), 27.07.2023.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Public Health and Surveillance, is properly cited. The complete bibliographic information, a link to the original publication on https://publichealth.jmir.org, as well as this copyright and license information must be included.

PMC Copyright notice

Meta-analyses on safety and efficacy profiles of CAB-LA and RPV-LA: (A) AE-related withdrawals: CAB-LA versus placebo [28,29], (B) AE-related withdrawal: RPV-LA versus placebo [33,34], and (C) confirmed HIV-1 infection: CAB-LA versus TDF-FTC [31,32]. AE: adverse event; CAB-LA: long-acting cabotegravir; RPV-LA: long-acting rilpivirine; TDF-FTC: tenofovir disoproxil fumarate–emtricitabine.